Seminars in Immunopathology

, 33:535

Death and inflammation following somatic cell transplantation

Review

DOI: 10.1007/s00281-011-0274-8

Cite this article as:
Copland, I.B. & Galipeau, J. Semin Immunopathol (2011) 33: 535. doi:10.1007/s00281-011-0274-8

Abstract

The fields of regenerative medicine and cellular therapy have been the subject of tremendous hype and hope. In particular, the perceived usage of somatic cells like mesenchymal stromal stem cells (MSCs) has captured the imagination of many. Clinical trials are currently evaluating the therapeutic efficacy of MSCs in disorders ranging from heart disease to pediatric graft-vs-host disease; however, numerous questions still remain regarding mechanism of action, effective dose, and whether these cells can be used in the allogeneic setting. One of the major issues surrounding the development of somatic cell therapies like MSCs is that despite evoking a positive response, long-term engraftment and persistence of these cells is rare. Consequently, very large cell doses need be administered raising production, delivery, and efficacy issues. In this review, we will discuss causes for this lack of persistence and highlight some of the methodologies be used to enhance cell survival post-transplantation.

Keywords

Programmed cell deathApoptosisAnoikis necrosisMesenchymal stem cellSomatic cellTransplantation

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Hematology and Medical OncologyEmory UniversityAtlantaUSA
  2. 2.School of MedicineEmory UniversityAtlantaUSA
  3. 3.Department of PediatricsEmory UniversityAtlantaUSA
  4. 4.Winship Cancer InstituteAtlantaUSA